Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Costa e Silva (Vila Nova de Gaia, Portugal), I. Sucena (Vila Nova de Gaia, Portugal), I. Ladeira (Vila Nova de Gaia, Portugal), I. Franco (Vila Nova de Gaia, Portugal), I. Pascoal (Vila Nova de Gaia, Portugal), A. Carvalho (Vila Nova de Gaia, Portugal), R. Lima (Vila Nova de Gaia, Portugal). Omalizumab in severe asthma: real life study. 2521

Member's Comments

No comment yet.

Related content which might interest you: Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey Source: Eur Respir J 2013; 42: 1224-1233 Year: 2013 Omalizumab significantly improves quality of life in patients with severe persistent allergic asthma: a pooled analysis Source: Eur Respir J 2005; 26: Suppl. 49, 49s Year: 2005 Omalizumab improves asthma-specific quality of life in patients with severe allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001 Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study Source: International Congress 2017 – Monitoring asthma control Year: 2017 Patients with asthma and comorbid allergic rhinitis: Is optimal quality of life achievable in real life? Source: Annual Congress 2011 - Asthma: risk factors and comorbidities Year: 2011 Omalizumab in severe uncontrolled asthma: two and a half year clinical experience Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Monitoring asthma in childhood: symptoms, exacerbations and quality of life Source: Eur Respir Rev 2015; 24: 187-193 Year: 2015 Real life experience with omalizumab and mepolizumab in severe asthma : do patient baseline features preclude effectiveness comparison ? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 One year following a real life experience of omalizumab for moderate to severe persistent allergic asthma in Malta Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Effectiveness of omalizumab in improving quality of life in patients with ‘steroid-resistant‘ asthma and severe allergic rhinitis Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2012 Real life study showing the epidemiological profile and adherence to treatment of patients with severe allergic asthma in use of omalizumab in the past year. Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Effect of omalizumab treatment on allergic comorbidities in patients with severe allergic asthma – real life experience from Czech Anti-IgE Registry Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Omalizumab in severe allergic asthma associated with COPD: a multicentric cohort study Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Small airway dysfunction in elderly patient with asthma: a real life study Source: International Congress 2018 – Clinical determinants of asthma and biomarkers Year: 2018 Improvement of control and quality of life in severe allergic asthmatics patients treated with omalizumab Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008 Asthma control in children-results of asthma in real life study in Poland Source: Eur Respir J 2002; 20: Suppl. 38, 453s Year: 2002 ‘Real-life‘ persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study Source: Annual Congress 2011 - Asthma management and response Year: 2011 Efficacy of Omalizumab in adult and pediatric severe allergic asthma according to presence of multiple allergic comorbidities: evidence from the STELLAIR study. Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Is quality of life impairment in asthma comparable to chronic urticaria? Source: Eur Respir J 2007; 30: Suppl. 51, 627s Year: 2007